Kumarakulasinghe, Nesaretnam Barr <br/><br/>
EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: a retrospective database analysis of potential drug interaction.  [electronic resource] 

 -  Oncotarget  Dec 2016 
 - 85542-85550 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>1949-2553 
<br/><br/><label>Standard No.: </label>10.18632/oncotarget.13458  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents--adverse effects<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Chi-Square Distribution<br/>Databases, Factual<br/>Disease Progression<br/>Disease-Free Survival<br/>Drug Interactions<br/>ErbB Receptors--antagonists & inhibitors<br/>Erlotinib Hydrochloride--pharmacology<br/>Female<br/>Gefitinib<br/>Humans<br/>Kaplan-Meier Estimate<br/>Karnofsky Performance Status<br/>Lung Neoplasms--drug therapy<br/>Male<br/>Middle Aged<br/>Multivariate Analysis<br/>Mutation<br/>Proportional Hazards Models<br/>Protein Kinase Inhibitors--adverse effects<br/>Proton Pump Inhibitors--adverse effects<br/>Quinazolines--pharmacology<br/>Retrospective Studies<br/>Risk Assessment<br/>Risk Factors<br/>Singapore<br/>Time Factors<br/>Treatment Outcome